首頁 > 市場調查報告書 > 製藥

藥物開發疫苗開發業務受託機關

市場調查報告書

商品編碼

1909181

疫苗契約製造市場規模、佔有率和成長分析（按研發階段、應用、工作流程、疫苗類型、產品類型、最終用戶、服務類型和地區分類）—2026-2033年產業預測

Vaccine Contract Manufacturing Market Size, Share, and Growth Analysis, By Phase, By Application, By Workflow, By Vaccine Type, By Type, By Product Type, By End User, By Service Type, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月01日 | 出版商:

SkyQuest | 英文 190 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球疫苗契約製造市場預計到 2024 年將達到 30.4 億美元，到 2025 年將達到 33 億美元，到 2033 年將達到 63.3 億美元，預測期（2026-2033 年）的複合年成長率為 8.5%。

市場趨勢表明，全球疫苗契約製造行業正經歷成長，這得益於疫苗接種舉措的擴大、技術的進步以及對疫情防範的重視。隨著各國啟動疫苗接種計劃，疫苗生產需求預計將會增加，尤其是在中低收入國家。 mRNA和病毒載體等先進技術可望進一步推動市場發展。此外，各國政府和國際衛生組織為建設生產能力提供的財政支持將確保即使在危機時期也能維持供應鏈的韌性。然而，基礎設施成本上升、法規環境嚴格、熟練勞動力短缺以及供應鏈脆弱性等挑戰可能會阻礙市場滲透。總體而言，在營運效率提高和市場壓力不斷增加的背景下，該產業蘊藏著巨大的產生收入潛力。

全球疫苗契約製造市場的促進因素

全球疫苗契約製造市場的主要促進因素之一是疫苗需求的不斷成長，而這又受到感染疾病發病率上升和人們對醫療保健日益重視的推動。新病原體和變種的出現，以及旨在根除疾病的全球衛生舉措，都催生了對快速且可擴展疫苗生產能力的需求。契約製造製造商憑藉其為成熟和新興生物技術公司提供必要的專業知識、基礎設施和柔軟性，在滿足這一需求方面佔據了戰略優勢。這一趨勢不僅提高了生產效率，還有助於疫苗的及時供應，從而推動了市場的整體成長。

全球疫苗契約製造市場面臨的限制因素

全球疫苗契約製造領域的一大市場限制因素是疫苗生產監管環境的嚴格性。企業必須遵守衛生當局的嚴格合規要求，包括繁瑣的測試和檢驗通訊協定，這可能導致延誤和成本增加。此外，公共衛生政策的波動和複雜的智慧財產權問題也會阻礙製造商與製藥公司之間的合作。不斷提高的品質標準要求也迫使製造商在先進技術和熟練勞動力方面投入巨資，這給中小企業設置了障礙，並限制了新進入者的市場准入。

全球疫苗契約製造市場趨勢

在全球疫苗契約製造市場，採用模組化和靈活的生產設施已成為一個顯著趨勢，從而提升了生產的靈活性和擴充性。供應商正擴大使用模組化潔淨室、預製單元和一次性生物反應器，以滿足多樣化的生產需求，並確保對市場波動做出快速反應。這項策略轉變支持多產品生產能力，使企業能夠最佳化運營，加快新型疫苗的上市速度。這一趨勢反映了整個行業對創新和效率的共同承諾，使契約製造製造商能夠更好地應對不斷變化的公共衛生需求和疫苗研發的動態環境。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Lonza Group（Switzerland）
Catalent, Inc.（USA）
Thermo Fisher Scientific Inc.（USA）
Samsung Biologics Co., Ltd.（South Korea）
WuXi Biologics（China）
FUJIFILM Diosynth Biotechnologies（Japan）
Emergent BioSolutions（USA）
IDT Biologika GmbH（Germany）
Charles River Laboratories（USA）
AGC Biologics（USA）
Boehringer Ingelheim BioXcellence（Germany）
Recipharm AB（Sweden）
CordenPharma（Germany）
KBI Biopharma（USA）
Merck KGaA（Germany）
Curia Global, Inc.（USA）
Siegfried Holding AG（Switzerland）
Novasep（France）
Richter-Helm BioLogics GmbH & Co. KG（Germany）
Syngene International Limited（India）

結論與建議

簡介目錄

Product Code: SQMIG35J2177

Global Vaccine Contract Manufacturing Market size was valued at USD 3.04 Billion in 2024 and is poised to grow from USD 3.3 Billion in 2025 to USD 6.33 Billion by 2033, growing at a CAGR of 8.5% during the forecast period (2026-2033).

Market insights indicate that the global vaccine contract manufacturing sector is experiencing growth driven by increased vaccination initiatives, advancements in technology, and a focus on pandemic preparedness. The demand for vaccine manufacturing is anticipated to rise, particularly in low- and middle-income countries, as countries launch immunization programs. Cutting-edge technologies, including mRNA and viral vectors, are set to further enhance market development. Additionally, government and global health funding aimed at building manufacturing capacity will ensure a resilient supply chain during crises. However, challenges such as high infrastructure costs, stringent regulatory environments, a shortage of skilled labor, and supply chain vulnerabilities may hinder market penetration. Overall, the sector presents significant revenue generation potential amid rising operational efficiencies and market pressures.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccine Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccine Contract Manufacturing Market Segments Analysis

Global Vaccine Contract Manufacturing Market is segmented by Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type and region. Based on Phase, the market is segmented into Preclinical, Clinical and Commercial. Based on Application, the market is segmented into Human Use and Veterinary. Based on Workflow, the market is segmented into Downstream, Upstream and Others. Based on Vaccine Type, the market is segmented into Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based. Based on Type, the market is segmented into Viral, Bacterial and Others. Based on Product Type, the market is segmented into Single Vaccines and Combination Vaccines. Based on End User, the market is segmented into Biopharmaceutical Companies and Research Academies & Government Institutes. Based on Service Type, the market is segmented into Fill-Finish and Bulk Products. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vaccine Contract Manufacturing Market

One of the key market drivers for the Global Vaccine Contract Manufacturing Market is the increasing demand for vaccines, fueled by rising incidences of infectious diseases and the growing focus on preventive healthcare. The emergence of new pathogens and variants, coupled with global health initiatives aimed at eradicating diseases, necessitates rapid and scalable vaccine production capabilities. Contract manufacturers are strategically positioned to meet this demand, providing essential expertise, infrastructure, and flexibility for both established and emerging biotechnology firms. This trend not only enhances production efficiency but also supports timely vaccine distribution, thus driving the overall growth of the market.

Restraints in the Global Vaccine Contract Manufacturing Market

A significant market restraint for the global vaccine contract manufacturing sector is the stringent regulatory landscape governing vaccine production. Companies face rigorous compliance requirements from health authorities, including extensive testing and validation protocols that can lead to delays and increased costs. Additionally, fluctuations in public health policies and the complexities of intellectual property rights can hinder collaboration between manufacturers and pharmaceutical firms. The increasing demand for high-quality standards also pressures manufacturers to invest heavily in advanced technology and skilled workforce, creating barriers for smaller firms and limiting market entry for new players.

Market Trends of the Global Vaccine Contract Manufacturing Market

The global vaccine contract manufacturing market is experiencing a significant trend toward the adoption of modular and flexible manufacturing facilities, enabling enhanced agility and scalability. Providers are increasingly utilizing modular cleanrooms, prefabricated units, and single-use bioreactors to meet diverse production demands and ensure rapid response to market fluctuations. This strategic shift supports multi-product manufacturing capabilities, allowing companies to optimize operations and reduce time-to-market for new vaccines. The trend reflects a broader industry commitment to innovation and efficiency, positioning contract manufacturers to better navigate evolving public health needs and the dynamic landscape of vaccine development.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Vaccine Contract Manufacturing Market Size by Phase & CAGR (2026-2033)

Market Overview
Preclinical
Clinical
Commercial

Global Vaccine Contract Manufacturing Market Size by Application & CAGR (2026-2033)

Market Overview
Human Use
Veterinary

Global Vaccine Contract Manufacturing Market Size by Workflow & CAGR (2026-2033)

Market Overview
Downstream
Upstream
Others

Global Vaccine Contract Manufacturing Market Size by Vaccine Type & CAGR (2026-2033)

Market Overview
Attenuated
Inactivated
Subunit-based
Toxoid-based
DNA-based

Global Vaccine Contract Manufacturing Market Size by Type & CAGR (2026-2033)

Market Overview
Viral
Bacterial
Others

Global Vaccine Contract Manufacturing Market Size by Product Type & CAGR (2026-2033)

Market Overview
Single Vaccines
Combination Vaccines

Global Vaccine Contract Manufacturing Market Size by End User & CAGR (2026-2033)

Market Overview
Biopharmaceutical Companies
Research Academies & Government Institutes

Global Vaccine Contract Manufacturing Market Size by Service Type & CAGR (2026-2033)

Market Overview
Fill-Finish
Bulk Products

Global Vaccine Contract Manufacturing Market Size & CAGR (2026-2033)

North America (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- US
- Canada
Europe (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- Brazil
- Rest of Latin America
Middle East & Africa (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Lonza Group (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FUJIFILM Diosynth Biotechnologies (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IDT Biologika GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AGC Biologics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim BioXcellence (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recipharm AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CordenPharma (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KBI Biopharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curia Global, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siegfried Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novasep (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Richter-Helm BioLogics GmbH & Co. KG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Syngene International Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments